COMP <GO>
AMRX vs ABVX // EV/EBITDA & P/E VALUATION
Amneal Pharmaceuticals Inc. (NASDAQ) VS. Abivax SA (NASDAQ) • 15-METRIC TALLY: AMRX 6
— ABVX 6
▲ EV/EBITDA & P/E VALUATION LEADER: ABVX
LAST: $20.44 (-4.97%) • MKT CAP: $7.49B
valuation
21.4x
LAST: $84.91 (-1.94%) • MKT CAP: $7.56B
valuation
21.0x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AMRX VS. ABVX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AMRX | ABVX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 36.90% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 14.10% | 9.90% | +4.20 | AMRX | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 21.4x | 21.0x | +0.40 | ABVX | /valuation <GO> |
| Free Cash Flow Yield | 3.63% | 2.21% | +1.42 | AMRX | /fcf-yield <GO> |
| Operating Margin | 13.10% | 13.90% | -0.80 | ABVX | /operating-margins <GO> |
| Net Profit Margin | 2.40% | 10.90% | -8.50 | ABVX | /net-margins <GO> |
| Revenue Growth (YoY) | 8.00% | 8.80% | -0.80 | ABVX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.83 | 3.74 | +0.09 | AMRX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 8/9 | +1.00 | AMRX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 66.6 | 41.0 | +25.60 | AMRX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.08 | 1.05 | +0.03 | AMRX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 96.0x | 30.5x | +65.50 | ABVX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $7.49B | $7.56B | -$63.5M | ABVX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AMRX REV | ABVX REV | AMRX GROSS % | ABVX GROSS % | AMRX FCF | ABVX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.02B | — | 36.9% | — | $269.9M | — |
| FY 2024 | $2.79B | — | 36.5% | — | $243.2M | — |
| FY 2023 | $2.39B | — | — | — | $237.9M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AMRX // BETA 1.08
ABVX // BETA 1.05